🚀
Enjoy a 7-Day Free Trial Thru Jan 19, 2025!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Strategies Created by Users
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Canadian Insider
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
Instant Alerts
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruAI
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
All Topics
General Discussions
Investment Ideas
Strategies
Article Comments
Books
Feedback
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Drug Manufacturers
Eli Lilly and Co (BUE:LLY)
News
Eli Lilly and Co - Cedear
0
BUE
:LLY (USA) Â
Cedear
ARS 16925.00
(+2.11%)
Jan 10
P/E:
86.48
P/B:
50.55
Market Cap:
ARS 745.81T
($ 720.15B)
Enterprise V:
ARS 774.51T
($ 747.86B)
Volume:
7.29K
Avg Vol (2M):
7.18K
Warning! GuruFocus detected 2 Medium warning signs with LLY.
Try a 7-Day Free Trial
to check it out.
Trade In:
Volume:
7.29K
Market Cap ARS:
745.81T
Market Cap $:
720.15B
PE Ratio:
86.48
Avg Vol (2M):
7.18K
Enterprise Value ARS:
774.51T
Enterprise Value $:
747.86B
PB Ratio:
50.55
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Forecast
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Eli Lilly and Co (BUE:LLY) Stock News, Headlines & Updates
Eli Lilly and Co Stock News from GuruFocus
Total 90
1
2
3
Jan 08, 2025
Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition
ShantiPutri
•
1:16pm
Jan 07, 2025
Eli Lilly and Co (LLY) to Participate in J.P. Morgan Healthcare Conference
GuruFocus News
•
10:01am
Lilly to participate in J.P. Morgan Healthcare Conference
PRNewswire
•
10:00am
Jan 02, 2025
Eli Lilly Stock Upgraded to "Buy" as Analysts Boost Price Target to $1,250
Nauman khan
•
9:06am
Multi-Billion Dollar Race to Combat Obesity
ShantiPutri
•
7:44am
Dec 30, 2024
Eli Lilly (LLY) Outperforms in Obesity Drug Market as Novo Nordisk (NVO) Struggles
GuruFocus News
•
6:10am
Dec 27, 2024
Tesla's Musk Uses Weight-Loss Drugs as Eli Lilly and Novo Nordisk Dominate the Market
Faizan Farooque
•
12:48pm
Dec 26, 2024
Market Today: Musk's Endorsement of Eli Lilly's Mounjaro and AMD's Acquisition Moves
GuruFocus News
•
4:32pm
Elon Musk Chooses Lilly's Mounjaro for Weight Loss Over Ozempic
GuruFocus News
•
12:50pm
Elon Musk's Weight-Loss Secret Shakes Up Pharma Giants
Khac Phu Nguyen
•
8:36am
GLP-1 Drugs Transform Obesity Treatment Amid Ethical Dilemmas
GuruFocus News
•
8:10am
Dec 21, 2024
Lilly's Zepbound Approved by FDA for Treating Sleep Apnea
GuruFocus News
•
3:30pm
Lilly's GLP-1 Drug Approved for Sleep Apnea Treatment, Boosting Market Edge
GuruFocus News
•
12:10am
Dec 20, 2024
FDA Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea in Adults with Obesity
GuruFocus News
•
4:02pm
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
PRNewswire
•
4:00pm
Eli Lilly (LLY) Shares Surge Over 7% Amid Novo Nordisk's Trial Results
GuruFocus News
•
9:31am
Dec 19, 2024
Eli Lilly's (LLY) Weight Loss Drug Supply Restored: FDA Halts Compounded Versions
GuruFocus News
•
3:30pm
Eli Lilly Resolves Weight Loss Drug Shortage, Novo Nordisk Still Facing Supply Issues
GuruFocus News
•
9:52am
Dec 17, 2024
Eli Lilly and Co (LLY) and EVA Pharma Announce Regulatory Approval of Locally Manufactured Insulin in Egypt
GuruFocus News
•
6:02am
Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
PRNewswire
•
6:00am
Novo Nordisk (NVO) and Eli Lilly (LLY) Face Acquisition Pressure Amid Obesity Drug Success
GuruFocus News
•
2:50am
Dec 13, 2024
Eli Lilly's Omvoh Receives Positive CHMP Opinion for Crohn's Disease Treatment
GuruFocus News
•
9:02am
Lilly's (LLY) Mounjaro Approved for Weight Management Including Sleep Apnea
GuruFocus News
•
8:30am
Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
PRNewswire
•
8:00am
Eli Lilly's (LLY) Mounjaro Gains Popularity Over Novo Nordisk's Wegovy in UK
GuruFocus News
•
6:30am
Dec 11, 2024
Eli Lilly's Imlunestrant Shows Promising Results in Advanced Breast Cancer Treatment
GuruFocus News
•
8:02am
Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
PRNewswire
•
8:00am
Dec 10, 2024
Eli Lilly (LLY) Announces $15 Billion Stock Buyback and Dividend Increase
GuruFocus News
•
8:50pm
Dec 09, 2024
Phase 3 Results for Eli Lilly's Pirtobrutinib Show Promising Outcomes in CLL/SLL Treatment
GuruFocus News
•
5:55pm
Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting
PRNewswire
•
5:00pm
Eli Lilly Announces $15 Billion Share Repurchase Program and Dividend Increase
GuruFocus News
•
4:03pm
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
PRNewswire
•
4:00pm
Eli Lilly and Co (LLY) Partners to Promote Kidney Health Awareness at 2025 Rose Parade
GuruFocus News
•
9:03am
CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade
PRNewswire
•
9:00am
Dec 06, 2024
Lilly (LLY) Invests $3 Billion to Expand U.S. Production for Diabetes and Weight Loss Drugs
GuruFocus News
•
10:10pm
Dec 05, 2024
Eli Lilly and Co (LLY) Announces $3 Billion Expansion of Wisconsin Manufacturing Facility
GuruFocus News
•
3:00pm
Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin
PRNewswire
•
3:00pm
The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials
ShantiPutri
•
8:10am
Dec 04, 2024
Eli Lilly's Zepbound Outperforms in Weight Loss, Boosting Market Position
GuruFocus News
•
12:04pm
Lilly's (LLY) Zepbound Outperforms Novo Nordisk's Wegovy in Weight Loss Trial
GuruFocus News
•
12:01pm
Total 90
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news